Novo Nordisk Type 2 Diabetes Drug Increases Weight Loss

Late-stage clinical trial shows patients taking Victoza reported a mean loss of 5.9 percent of body weight

June 16, 2014

Novo Nordisk's diabetes drug Victoza appears to be an effective weight loss therapy, according to data from a late-stage clinical trial. In a 56-week study of 846 overweight or obese adults with type 2 diabetes, a daily injection of 3 milligrams of Victoza led to significantly greater weight loss than did a placebo. Read the full story